Encorafenib-13C,d3

Encorafenib-13C,d3

• UNSPSC Description: Encorafenib-13C,d3 is the 13C- and deuterium labeled Encorafenib. Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
• Target Antigen: Isotope-Labeled Compounds; Raf
• Type: Isotope-Labeled Compounds
• Related Pathways: MAPK/ERK Pathway;Others
• Field of Research: Cancer
• Solubility: 10 mM in DMSO
• Smiles: O=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)([13C]([2H])([2H])[2H])=O)=C3F)=N1
• Molecular Weight: 544.02
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Compounds and compositions as protein kinase inhibitors
. Patent WO 2011025927 A1|[3]Li Z, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported